This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Attorneys on the plaintiff's side, who are arguing that the vaccine caused injur...
Human medicines European public assessment report (EPAR): Lenvima, lenvatinib, D...
A popular awareness campaign now in its second year that encouraged people to ge...
This is the web edition of STAT’s Health Tech newsletter, our guide to how techn...
The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foot...
Prescription totals for Attruby, which is locked in a closely watched commercial...
BioMed X Institute is teaming up with the Barbados government in an effort to ac...
Human medicines European public assessment report (EPAR): Fabhalta, Iptacopan, D...
Human medicines European public assessment report (EPAR): Victoza, liraglutide, ...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
Development of the Clinical Trials Information System
Minutes of the CVMP meeting 14-15 January 2025
The latest from the biopharma world, brought to you by The Readout.
In today's Pharmalittle roundup, Trump and pharma tariffs, losing too much weigh...
UroGen Pharma has opened another front in its attack on bladder cancer, paying I...
Orphan designation: Rilzabrutinib Treatment of autoimmune haemolytic anaemia, 16...
Grad school applicants in limbo, muscle dysmorphia, and other health news storie...
Orphan designation: Clofutriben Treatment of Cushing's syndrome of endogenous or...
Jagsonpal Pharmaceuticals and Tyche Industries, both makers of APIs based in Ind...
AstraZeneca is paying $160 million for FibroGen’s Chinese business, giving the U...
Orphan designation: zopapogene imadenovec Treatment of recurrent respiratory pap...
Orphan designation: N-(2-Methoxyethyl)-6-methyl-N-[(3-methyl-2-thienyl)methyl]-2...